Kelun-Biotech's TROP2-ADC SKB264 Study Results at 2024 CSCO Congress

From September 25th to 29th, the 27th China Clinical Oncology Congress and the 2024 CSCO Annual Meeting took place in Xiamen. This significant event drew together oncology experts and scholars from across China to deliberate on the latest advancements and trends in clinical oncology practice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK) prominently featured at the conference, showcasing various clinical research findings and developments related to the TROP2 ADC sacituzumab tirumotecan (sac-TMT), previously known as SKB264/MK-2870.

The conference served as a comprehensive platform for leading oncologists to present cutting-edge research and exchange insights on cancer treatment. Kelun-Biotech’s sacituzumab tirumotecan was a focal point of several presentations, underlining its potential as a promising therapeutic option in oncology.

One notable highlight was the oral report delivered by Academician Binghe Xu. His presentation provided an in-depth analysis of the clinical trials involving sac-TMT, emphasizing its efficacy and safety profile. Xu's data highlighted significant improvements in patient outcomes, particularly in individuals with advanced cancers who had limited treatment options.

Professor Wengfeng Fang also presented an oral report that delved into the mechanism of action of sac-TMT. Fang's research underscored the drug's targeted approach in attacking cancer cells while minimizing damage to healthy tissues. This targeted therapy represents a significant advancement in reducing the adverse side effects commonly associated with conventional cancer treatments.

In another key presentation, Professor Jing Wang focused on the clinical application of sac-TMT in treating triple-negative breast cancer (TNBC). TNBC is known for its aggressive nature and limited treatment options. Wang's findings demonstrated that sac-TMT offers a new line of defense against this challenging form of breast cancer, showing promising results in clinical trials.

Dr. Zhuo Yang also contributed to the discussions with an oral report examining the broader implications of sac-TMT in oncology. Yang's insights covered the drug's potential in treating various other cancer types beyond TNBC. His report highlighted ongoing studies that are exploring the efficacy of sac-TMT in different oncological contexts, aiming to expand its application and benefit a larger patient population.

Throughout the conference, the collective presentations painted a picture of sac-TMT as a versatile and potent anti-cancer agent. The research showcased by Kelun-Biotech underscored the importance of continued innovation and collaboration in the field of oncology. The company's focus on developing targeted therapies aligns with the broader goal of improving patient outcomes and advancing cancer treatment.

The 27th China Clinical Oncology Congress and the 2024 CSCO Annual Meeting provided a valuable forum for the exchange of knowledge and ideas. The event highlighted the ongoing efforts and achievements in oncology research, with sacituzumab tirumotecan standing out as a notable example of progress in the fight against cancer.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!